Targeting LRP6: A new strategy for cancer therapy

Targeting specific molecular drivers of tumor growth is a key approach in cancer therapy. Among these targets, the low-density lipoprotein receptor-related protein 6 (LRP6), a vital component of the Wnt signaling pathway, has emerged as an intriguing candidate. As a cell-surface receptor and vital c...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Xue (Author), Bo Zhu (Author), Kaili Zhao (Author), Qiuju Huang (Author), Hua Luo (Author), Yiwen Shou (Author), Zhaoquan Huang (Author), Hongwei Guo (Author)
Format: Book
Published: Elsevier, 2024-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d1629e0a3f4a47d38db62d965f9b1a17
042 |a dc 
100 1 0 |a Wei Xue  |e author 
700 1 0 |a Bo Zhu  |e author 
700 1 0 |a Kaili Zhao  |e author 
700 1 0 |a Qiuju Huang  |e author 
700 1 0 |a Hua Luo  |e author 
700 1 0 |a Yiwen Shou  |e author 
700 1 0 |a Zhaoquan Huang  |e author 
700 1 0 |a Hongwei Guo  |e author 
245 0 0 |a Targeting LRP6: A new strategy for cancer therapy 
260 |b Elsevier,   |c 2024-06-01T00:00:00Z. 
500 |a 1096-1186 
500 |a 10.1016/j.phrs.2024.107200 
520 |a Targeting specific molecular drivers of tumor growth is a key approach in cancer therapy. Among these targets, the low-density lipoprotein receptor-related protein 6 (LRP6), a vital component of the Wnt signaling pathway, has emerged as an intriguing candidate. As a cell-surface receptor and vital co-receptor, LRP6 is frequently overexpressed in various cancer types, implicating its pivotal role in driving tumor progression. The pursuit of LRP6 as a target for cancer treatment has gained substantial traction, offering a promising avenue for therapeutic intervention. Here, this comprehensive review explores recent breakthroughs in our understanding of LRP6's functions and underlying molecular mechanisms, providing a profound discussion of its involvement in cancer pathogenesis and drug resistance. Importantly, we go beyond discussing LRP6's role in cancer by discussing diverse potential therapeutic approaches targeting this enigmatic protein. These approaches encompass a wide spectrum, including pharmacological agents, natural compounds, non-coding RNAs, epigenetic factors, proteins, and peptides that modulate LRP6 expression or disrupt its interactions. In addition, also discussed the challenges associated with developing LRP6 inhibitors and their advantages over Wnt inhibitors, as well as the drugs that have entered phase II clinical trials. By shedding light on these innovative strategies, we aim to underscore LRP6's significance as a valuable and multifaceted target for cancer treatment, igniting enthusiasm for further research and facilitating translation into clinical applications. 
546 |a EN 
690 |a LRP6 
690 |a Wnt/β-catenin signaling pathway 
690 |a Cancer treatment 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Pharmacological Research, Vol 204, Iss , Pp 107200- (2024) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S1043661824001440 
787 0 |n https://doaj.org/toc/1096-1186 
856 4 1 |u https://doaj.org/article/d1629e0a3f4a47d38db62d965f9b1a17  |z Connect to this object online.